Form 4: Xilio Therapeutics Director Sara Bonstein Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director Sara Bonstein was granted 31,000 stock options with an exercise price of $0.693, vesting fully by June 2026 or the next annual meeting.

Summary

• Sara Bonstein, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options on June 11, 2025.
• The options have an exercise price of $0.693 per share.
• The options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Bonstein's continued service to the Issuer through the vesting date.
• The stock options are set to expire on June 10, 2035.
• Following this transaction, Ms. Bonstein beneficially owns 31,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice that aligns management interests with shareholders, which is generally viewed positively. It does not indicate any immediate financial distress or significant negative news, making the sentiment slightly positive.

Positives

• The grant of stock options to Director Sara Bonstein aligns her financial interests with those of the shareholders, as the options gain value only if the company's stock price increases above the exercise price of $0.693.
• The vesting schedule encourages long-term commitment and continued service from a key board member, contributing to stable governance.

Negatives

• While not an immediate negative, the future exercise of these options could lead to a minor dilution of existing shareholders' equity, as new shares would be issued.

Risks

• The value of the stock options is entirely dependent on Xilio Therapeutics' common stock price exceeding the exercise price of $0.693; if the stock price remains below this level, the options may expire worthless.
• The options are subject to forfeiture if the Reporting Person's service to the Issuer ceases before the specified vesting date.

Future Outlook

The vesting schedule indicates that Sara Bonstein's stock options will fully vest by June 11, 2026, or the company's next annual meeting, provided she continues her service as a Director. This implies an expectation of her continued involvement with the company for at least the next year.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, particularly for early-stage companies like Xilio Therapeutics. This compensation method is widely used to attract and retain experienced board members, align their incentives with long-term company performance, and conserve cash.

Comparison to Industry Standards

• It is standard practice for directors in biotech companies to receive equity compensation, including stock options, as part of their overall remuneration package.
• To assess if the specific number of options (31,000) and the exercise price ($0.693) align with industry benchmarks, a detailed comparison against director compensation policies of similar-sized and stage-appropriate biotech companies (e.g., small-cap oncology-focused biotechs) would be required. Without such specific comparable data, a precise assessment is not feasible.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives that encourage long-term value creation.
• Employees, Customers, Suppliers, Creditors: No direct impact mentioned in this filing.

Next Steps

• The options are expected to vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to Sara Bonstein's continued service.
• Sara Bonstein may choose to exercise her options at any time after vesting and before the expiration date of June 10, 2035, provided the stock price is favorable.

Key Dates

Recommendation

Keywords

Xilio Therapeutics, XLO, SEC Form 4, insider transaction, stock option, director compensation, equity grant, Sara Bonstein, beneficial ownership